Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARMP 
Armata Pharmaceuticals Inc (ARMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.32% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 92.75M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 1 | 52 Weeks Range 0.90 - 2.96 | Updated Date 08/28/2025 |
52 Weeks Range 0.90 - 2.96 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.39 | Actual -0.45 |
Profitability
Profit Margin - | Operating Margin (TTM) -315.54% |
Management Effectiveness
Return on Assets (TTM) -23.35% | Return on Equity (TTM) -3439.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 232375395 | Price to Sales(TTM) 13.5 |
Enterprise Value 232375395 | Price to Sales(TTM) 13.5 | ||
Enterprise Value to Revenue 148.14 | Enterprise Value to EBITDA 15.72 | Shares Outstanding 36229800 | Shares Floating 10874749 |
Shares Outstanding 36229800 | Shares Floating 10874749 | ||
Percent Insiders 69.48 | Percent Institutions 2.02 |
Upturn AI SWOT
Armata Pharmaceuticals Inc
Company Overview
History and Background
Armata Pharmaceuticals Inc. was founded in 2003 as AmpliPhi Biosciences Corporation and later rebranded. The company focuses on developing bacteriophage therapeutics to combat antibiotic-resistant infections.
Core Business Areas
- Phage-based Therapeutics: Develops and commercializes bacteriophage-based therapies targeting antibiotic-resistant bacteria.
Leadership and Structure
Armata Pharmaceuticals Inc. is led by a management team with experience in biotechnology and pharmaceuticals. The structure includes executive leadership and research and development teams focused on phage therapy.
Top Products and Market Share
Key Offerings
- AP-PA02: A product candidate targeting Pseudomonas aeruginosa infections. Market share data unavailable as it's still in clinical trials. Competitors include companies developing novel antibiotics and other anti-infective therapies.
- AP-SA02: A clinical-stage product candidate targeting Staphylococcus aureus (S. aureus) infections. Market share data unavailable as it's still in clinical trials. Competitors include companies developing novel antibiotics and other anti-infective therapies.
Market Dynamics
Industry Overview
The antibiotic resistance market is growing due to the increasing prevalence of drug-resistant infections. Bacteriophage therapy is gaining traction as an alternative approach.
Positioning
Armata Pharmaceuticals Inc. is a key player in the phage therapy field, focused on developing targeted therapies for antibiotic-resistant bacteria. Competitive advantages include proprietary phage libraries and development expertise.
Total Addressable Market (TAM)
The TAM for antibiotic-resistant infections is estimated to be in the tens of billions of dollars annually. Armata is positioned to capture a share of this market through its targeted phage therapies. The global antimicrobial therapeutics market size was valued at USD 56.1 billion in 2023 and is projected to grow from USD 60.22 billion in 2024 to USD 97.32 billion by 2032.
Upturn SWOT Analysis
Strengths
- Proprietary phage library
- Expertise in bacteriophage development
- Potential for targeted therapies
- Addresses antibiotic resistance
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Regulatory hurdles for phage therapy
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Advancements in phage engineering
- Increased awareness of phage therapy
Threats
- Competition from other antibiotic alternatives
- Regulatory setbacks
- Clinical trial failures
- Emergence of phage resistance
Competitors and Market Share
Key Competitors
- DHRM
- ADMP
- SNGX
Competitive Landscape
Armata Pharmaceuticals Inc. competes with other companies developing anti-infective therapies. Armata's advantage lies in its phage-based approach. Disadvantages are high cash burn and risks relating to R&D activities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by periods of clinical trial progress and setbacks, impacting stock price.
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for AP-SA02 and AP-PA02 and seeking partnerships.
Summary
Armata Pharmaceuticals is a biopharmaceutical company specializing in bacteriophage therapy, a promising alternative to traditional antibiotics. The company faces financial challenges and depends on successful clinical trials for its pipeline products. Positive clinical trial results and strategic partnerships could improve its position. However, competition and regulatory hurdles remain significant concerns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
- Financial News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Armata Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2011-03-09 | CEO & Director Dr. Deborah L. Birx M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.armatapharma.com |
Full time employees 60 | Website https://www.armatapharma.com | ||
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.